Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Sharp

Showing results (71-80 of 113) with videos related to

Pageof 12
Sort By:
The Journal of Clinical Investigation|April 1, 2026
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancersAlec Paschalis, Ines Figueiredo, Denisa Bogdan, et al.
Oncogene|September 12, 2024
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancerSumaira Sardar, Christopher M McNair, Lakshmi Ravindranath, et al.
European Urology Oncology|March 12, 2026
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate CancerRafael Grochot, Christina Guo, Suzanne Carreira, et al.
Nature Medicine|June 27, 2025
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trialSusana Banerjee, Matthew G Krebs, Alastair Greystoke, et al.
Investigational New Drugs|May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancerKhobe Chandran, Christina Guo, Simon Pacey, et al.
Cell Reports|January 19, 2018
BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate CancerXiangyi Li, GuemHee Baek, Susmita G Ramanand, et al.
European Urology|September 4, 2017
Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate CancerYezi Zhu, Adam Sharp, Courtney M Anderson, et al.
Oncogene|May 3, 2019
Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancerClaire E Fletcher, Eric Sulpice, Stephanie Combe, et al.
Nature|June 29, 2018
IL-23 secreted by myeloid cells drives castration-resistant prostate cancerArianna Calcinotto, Clarissa Spataro, Elena Zagato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
Characterizing CDK12-Mutated Prostate CancersPasquale Rescigno, Bora Gurel, Rita Pereira, et al.
Pageof 12

Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
The Journal of Clinical Investigation|April 1, 2026
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancersAlec Paschalis, Ines Figueiredo, Denisa Bogdan, et al.
Oncogene|September 12, 2024
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancerSumaira Sardar, Christopher M McNair, Lakshmi Ravindranath, et al.
European Urology Oncology|March 12, 2026
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate CancerRafael Grochot, Christina Guo, Suzanne Carreira, et al.
Nature Medicine|June 27, 2025
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trialSusana Banerjee, Matthew G Krebs, Alastair Greystoke, et al.
Investigational New Drugs|May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancerKhobe Chandran, Christina Guo, Simon Pacey, et al.
Cell Reports|January 19, 2018
BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate CancerXiangyi Li, GuemHee Baek, Susmita G Ramanand, et al.
European Urology|September 4, 2017
Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate CancerYezi Zhu, Adam Sharp, Courtney M Anderson, et al.
Oncogene|May 3, 2019
Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancerClaire E Fletcher, Eric Sulpice, Stephanie Combe, et al.
Nature|June 29, 2018
IL-23 secreted by myeloid cells drives castration-resistant prostate cancerArianna Calcinotto, Clarissa Spataro, Elena Zagato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2020
Characterizing CDK12-Mutated Prostate CancersPasquale Rescigno, Bora Gurel, Rita Pereira, et al.
Pageof 12